DNBSEQ[™] SERVICE OVERVIEW Whole Exome Sequencing

BG

Service Description

For many applications, Whole Exome Sequencing is gaining popularity as a viable and cost-effective alternative for Whole Genome Sequencing. BGI has performed professional exome sequencing services for many years at several locations around the world, to support human and animal (rodents and monkeys) research and to benefit small and large-scale clinical trials and pharmaceutical drug development projects.

Besides raw sequencing data output, BGI offers standard and custom bioinformatics services to suit your specific research needs.

Sequencing Service Specification

BGI Human Exome Sequencing Service are performed with the DNBSEQ sequencing technology, featuring cPAS and DNA Nanoballs(DNB[™]) for superior data quality.



Sample Preparation and Services

- Agilent Sureselect or IDT xGen exome kit for library construction and enrichment, 100/150bp paired-end sequencing options available
- Clean data and advanced bioinformatics analysis are available in standard file formats
- · Standard and custom bioinformatics data analysis
- · Available data storage and bioinformatics applications



Sequencing Quality Standard

- Guaranteed ≥80% of bases with quality score of ≥Q30
- Standard sequencing coverage ≥50X; ≥100x is recommended for cancer samples



🗸 🔾 Quality Data

Turn Around Time

· Typical 25 days after sample acceptance for data delivery

€


Cost Effective

10 days for rapid delivery service

Fast TAT

Project Workflow

We care for your samples from the start through to the result reporting. Highly experienced laboratory professionals follow strict quality procedures to ensure the integrity of your results.



Data Analysis

Besides clean data output, BGI offers a range of standard and customized bioinformatics pipelines for your whole exome sequencing project.

Reports and output data files are delivered in industry standard file formats: BAM, VCF, .xls, .png

CANCER MUTATION ANALYSIS

- Data Filtering and QC
- · Align reads to the human reference genome
- Germline SNP/InDel detection
- Somatic SNV detection .
- Somatic InDel detection
- · Somatic CNV detection
- Tumor purity and ploidy analysis
- Verification of homology of paired samples

- Susceptibility gene screening
- Drug Targeted Annotation
- Driving gene prediction
- Identifying Significant Mutated Genes
- Deciphering Mutational Signature
- CN-neutral Loss of Heterozygosity
- Hyper-mutated Sample Classification
- Clone Analysis

HUMAN- MENDELIAN DISORDERS ANALYSIS

- Data filtering
- Align reads to the human reference genome
- Variants calling
- **VEP** annotation .
- Public group AF annotation ٠
- Harmful or conservative prediction tools
- Signaling pathway annotation .
- **OMIM** annotation .

- · Normal tissue protein expression annotation
- classification criteria and guidelines
- · De novo mutation screening
- Analysis of family co-separation

OTHER AVAILABLE ADVANCED ANALYSIS

- Population genetics analysis De novo mutation analysis for family samples
- Tumor neoantigen prediction Complex disease analysis

CUSTOMIZED ANALYSIS

Further customization of Bioinformatics analysis to suit your unique project is available:

Please contact your BGI technical representative

Sample Requirements

We can process your gDNA, Blood, Cell line, Fresh frozen tissue samples from a variety of species, with the following general requirements:

Sample type	Mass	Concentration	Integrity (AGE)	Sample Purity
Genomic DNA	≥1µg	≥12.5ng/µL	The band shown on gel electrophoresis has little degradation, or of fragment size greater than 20kb.	No contamination with RNA,protein or salt ions; colorless and transparent; non-sticky.

- · Data screening and interpretation
 - · Screening according to ACMG genetic variation
 - · Screening by threshold
- · RoH analysis

DNBSEQ Sequencing Technology


DNBSEQ system is an industry leading high-throughput sequencing solution, powered by combinatorial Probe-Anchor Synthesis (cPAS) and improved DNA Nanoballs (DNB[™]) technology. The cPAS chemistry works by incorporating a fluorescent probe to a DNA anchor on the DNB[™], followed by high-resolution digital imaging. This combination of linear amplification and DNB[™] technology reduces the error rate while enhancing the signal. In addition, the size of the DNB[™] is controlled in such a way that only one DNB[™] is bound per active site. This patterned array technology not only provides sequencing accuracy, but it also increases the chip utilization and sample density.

Sequencing Technology References

Drmanac R, Sparks AB, Callow MJ,Halpern AL, Burns NL, Kermani BG, Carnevali P et al. Human genome sequencing using unchained base reads on selfassembling DNA nanoarrays. *Science*. 2010;327(5961):78–81.


Data Performance

Following is an example of typical DNBSEQ data output for a 100X WES project with standard sample NA12878, compared with data from the Illumina HiSeq 4000 system.



Bar-Graph showing the mapping rate and sequencing coverage of the samples using DNBSEQ and Illumina HiSeq 4000 platform of 100X WES.

SNP calling performance from the NA12878 standard sample demonstrates good concordance between platforms



InDel calling performance from the NA12878 standard sample demonstrates good concordance between platforms.

*Full demonstration data reports are available through your BGI account representative.

Request Information or Quotation

Contact your BGI account representative for the most affordable rates in the industry, to discuss how we can meet your specific project requirements or for expert advice on experiment design, from sample to bioinformatics.

info@bgi.com

www.bgi.com

BGI Offices

BGI Americas

One Broadway, 14th Floor Cambridge, MA 02142, USA **BGI Europe** Ole Maaløes Vej 3,

DK-2200 Copenhagen N, Denmark

BGI Asia

Building NO.7, BGI Park, No.21 Hongan 3rd Street, Yantian District, Shenzhen

BGI Australia

L6, CBCRC, 300 Herston Road, Herston, Brisbane, Queensland 4006, Australia



For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

Copyright© BGI 2022. All trademarks are the property of BGI, or their respective owners. This material contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Note, BGI's genetic testing products have not been cleared or approved by the US FDA and are not available in the USA. For Research Use Only. Unless otherwise informed, all sequencers and sequencing reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium or Italy. Certain sequencing services are not available in USA and Hong Kong. Please contact a representative for regional availability. The company reserves the right of final interpretation.

